Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.41 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.40 |
| ▸ | CTSC | P53634 | 7/20 | 0.39 |
| ▸ | CTSK | P43235 | 5/20 | 0.39 |
| ▸ | SGK1 | O00141 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579724 | 0.81 | PGR (0.50) | PRKCQPRKCDHSP90AA1PIM1 | |
| SCHEMBL4582021 | 0.80 | HSP90AA1 (0.52) | EML4ALKHSP90AA1 | |
| SCHEMBL4580296 | 0.79 | PIM1 (0.44) | PRKCQPRKCDHSP90AA1PIM1 | |
| SCHEMBL4580711 | 0.77 | HSP90AA1 (0.45) | PRKCQPRKCDSGK1HSP90AA1 | |
| SCHEMBL4580882 | 0.77 | HSP90AA1 (0.46) | PRKCQPRKCDHSP90AA1 | |
| SCHEMBL4580648 | 0.76 | PRKCQ (0.43) | PRKCQPRKCDSGK1HSP90AA1 | |
| SCHEMBL14252710 | 0.76 | PRKCQ (0.43) | PRKCQPRKCDSGK1HSP90AA1PIM1 | |
| SCHEMBL4582583 | 0.76 | PRKCQ (0.44) | PRKCQPRKCDHSP90AA1 | |
| SCHEMBL4579980 | 0.75 | KDM4E (0.48) | PRKCQPRKCDHSP90AA1 | |
| SCHEMBL4579571 | 0.74 | KMT2A (0.45) | PRKCQPRKCDCTSKCTSSHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | claimed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008024963-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076800-A1 | Benzene, Pyridine, and Pyridazine Derivatives | RB1, MKI67, CCNB1 | NR1H2 681/4885PRKCQ 4430/4885EML4 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.